Measles Mumps And Rubella clinical trials

Explore recruiting measles mumps and rubella clinical trials.

Recruiting measles mumps and rubella studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Measles Mumps And Rubella trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The induction of respiratory immune responses by epicutaneous vaccination with the MMR vaccine

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3a, observer-blind, randomized, controlled study to evaluate the safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.

Lithuania, Poland, Bulgaria, Estonia, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

EarLy extra Measles immunisation during a measles Outbreak (ELMO)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared with Varivax, When Given as a Second Dose to Healthy Children, 3 Months after the Administration of a First Dose at 12 to 15 Months of age

Denmark, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

Measles Mumps And Rubella trials by city

Measles Mumps And Rubella clinical trials

Recruiting measles mumps and rubella studies right now

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Also recruiting in Europe

The induction of respiratory immune responses by epicutaneous vaccination with the MMR vaccine

A Phase 3a, observer-blind, randomized, controlled study to evaluate the safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).

EarLy extra Measles immunisation during a measles Outbreak (ELMO)

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared with Varivax, When Given as a Second Dose to Healthy Children, 3 Months after the Administration of a First Dose at 12 to 15 Months of age

Measles Mumps And Rubella trials by city

Other conditions